Gilead Sciences, Inc. Shareholders Decimate Plan To Tie CEO Compensation To Drug Access

Gilead Sciences Inc. shareholders thumped a proposal Wednesday that would have tied the compensation of CEO John Martin to patient access to the company's groundbreaking drugs. The plan captured only 2 percent of the vote of Foster City-based Gilead's (NASDAQ: GILD) roughly 1.5 billion outstanding shares. It asked Gilead's board to include non-financial measures based on patient access to the company's drugs in determining CEO compensation.

Help employers find you! Check out all the jobs and post your resume.